104 related articles for article (PubMed ID: 18324596)
1. PET/CT in malignant bone disease.
Even-Sapir E
Semin Musculoskelet Radiol; 2007 Dec; 11(4):312-21. PubMed ID: 18324596
[TBL] [Abstract][Full Text] [Related]
2. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities.
Even-Sapir E
J Nucl Med; 2005 Aug; 46(8):1356-67. PubMed ID: 16085595
[TBL] [Abstract][Full Text] [Related]
3. PET and PET/CT in pediatric oncology.
Jadvar H; Connolly LP; Fahey FH; Shulkin BL
Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
[TBL] [Abstract][Full Text] [Related]
4. F-18 FDG PET/CT staging of multiple myeloma with diffuse osseous and extramedullary lesions.
Wiesenthal AA; Nguyen BD
Clin Nucl Med; 2007 Oct; 32(10):797-801. PubMed ID: 17885362
[TBL] [Abstract][Full Text] [Related]
5. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
[TBL] [Abstract][Full Text] [Related]
7. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
8. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
[TBL] [Abstract][Full Text] [Related]
9. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
10. FDG PET/CT flip flop phenomenon in treated lymphoma of bone.
Lin EC
Clin Nucl Med; 2006 Dec; 31(12):803-5. PubMed ID: 17117078
[TBL] [Abstract][Full Text] [Related]
11. Assessing tumor response to therapy.
Weber WA
J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
[TBL] [Abstract][Full Text] [Related]
12. PET/CT in musculoskeletal infection.
Strobel K; Stumpe KD
Semin Musculoskelet Radiol; 2007 Dec; 11(4):353-64. PubMed ID: 18324599
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 18F-FDG positron emission tomography and computed tomography in patients with colorectal carcinoma and lymphoma: our initial clinical experience.
Coha B; Radmilović K; Gardasanić J; Daković M; Stefanić M; Latić A; Mitrecić D
Acta Clin Croat; 2009 Mar; 48(1):35-9. PubMed ID: 19623870
[TBL] [Abstract][Full Text] [Related]
14. Fever of unknown origin: the role of 18F-FDG PET/CT.
Keidar Z; Gurman-Balbir A; Gaitini D; Israel O
J Nucl Med; 2008 Dec; 49(12):1980-5. PubMed ID: 18997040
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
16. PET/CT for therapy response assessment in lymphoma.
Hutchings M; Barrington SF
J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
[TBL] [Abstract][Full Text] [Related]
17. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
18. Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT.
Hanrahan CJ; Christensen CR; Crim JR
Radiographics; 2010 Jan; 30(1):127-42. PubMed ID: 20083590
[TBL] [Abstract][Full Text] [Related]
19. Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature.
Dong MJ; Zhao K; Lin XT; Zhao J; Ruan LX; Liu ZF
Nucl Med Commun; 2008 Sep; 29(9):791-802. PubMed ID: 18677207
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
